Across TCGA pan-cancer cohorts, OR7E36P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR7E36P data layer compared with 11 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR7E36P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR7E36P expression acts as an unfavorable survival marker.
OV are the cancer types where OR7E36P Mutation most reproducibly stratifies survival.